The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Virtual navigation (VNav) provides access to quality care: Program facilitates self-advocacy in cancer care.
 
Joyce Rosemarie Schaffer
No Relationships to Disclose
 
Susan Haag
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - 2X Oncology; 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Araxes Pharma; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BeyondSpring Pharmaceuticals; Bicycle Therapeutics; BiolineRx; Bionomics; Biospecifics Technologies; Boston Biomedical; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; CORRONA; CV6 Therapeutics; CytomX Therapeutics; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Formula Pharmaceuticals; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gilead Sciences; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Innokeys; Insys Therapeutics; Intezyne Technologies; Ipsen; Jounce Therapeutics; Kalos Therapeutics; Kura Oncology; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Medical Prognosis Institute; miRNA Therapeutics; Novita Pharmaceuticals; Novocure; Nucana; Oncology Venture; Oncolytics; Oncolyze; Orphagen Pharmaceuticals; Pain Therapeutics; Pharmamab; Phosplatin Therapeutics; Reflexion Medical; RenovoRx; Riptide Bioscience; Samus Therapeutics; SciClone; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Synergene; Systems Imagination; TargaGenix; Tavistock Life Sciences; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trans Med; Trovagene; Veana Therapeutics; Ventana Medical Systems; Verily; Vertex; Viamet Pharmaceuticals; Vicus Therapeutics
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Genentech/Roche
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)